Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A : Data from the PedNet Study Group

de Kovel, Marloes ; van Haaster, Aimée-Claire ; Carcao, Manuel ; Ranta, Susanna ; Glosli, Heidi ; Rivard, Georges E ; Kenet, Gili ; Kurnik, Karin ; Van Geet, Christel and Carvalho, Manuela , et al. (2025) In Haemophilia
Abstract

INTRODUCTION: Inhibitor development against factor VIII (FVIII) is the most common complication of hemophilia A replacement therapy. One of the variables considered to influence inhibitor development is the ABO blood group. Patients with blood group O have, on average, a 30%-40% lower endogenous von Willebrand factor (VWF) concentration. It has been postulated that VWF levels influence inhibitor development. The objective of this study was to investigate the inhibitor risk in patients with severe hemophilia A comparing those with blood group O with those with non-O blood groups.

METHODS: The study population consisted of children with severe hemophilia A, born between 2000 and 2020, who reached 50 FVIII exposure days in the PedNet... (More)

INTRODUCTION: Inhibitor development against factor VIII (FVIII) is the most common complication of hemophilia A replacement therapy. One of the variables considered to influence inhibitor development is the ABO blood group. Patients with blood group O have, on average, a 30%-40% lower endogenous von Willebrand factor (VWF) concentration. It has been postulated that VWF levels influence inhibitor development. The objective of this study was to investigate the inhibitor risk in patients with severe hemophilia A comparing those with blood group O with those with non-O blood groups.

METHODS: The study population consisted of children with severe hemophilia A, born between 2000 and 2020, who reached 50 FVIII exposure days in the PedNet registry. Inhibitors were considered to be clinically relevant when at least two consecutive measurements were tested positive.

RESULTS: Routine testing of blood groups varied between centres: Out of 1172 patients with severe hemophilia A, blood group status was known in 759 patients (65.8%). The relative risk of inhibitor development for blood group O in comparison to non-O was 1.04 (95% CI: 0.7-1.7).

CONCLUSION: In the PedNet cohort, blood group O did not increase the risk of inhibitors in previously untreated children with severe hemophilia A.

TRIAL REGISTRATION: PedNet Registry; clinicaltrials.gov identifier: NCT02979119.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
Haemophilia
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:105000949649
  • pmid:40123267
ISSN
1351-8216
DOI
10.1111/hae.70035
language
English
LU publication?
yes
additional info
© 2025 John Wiley & Sons Ltd.
id
47a494f7-0ba7-41da-bab0-3658e6f04c09
date added to LUP
2025-03-29 18:28:22
date last changed
2025-07-01 07:04:40
@article{47a494f7-0ba7-41da-bab0-3658e6f04c09,
  abstract     = {{<p>INTRODUCTION: Inhibitor development against factor VIII (FVIII) is the most common complication of hemophilia A replacement therapy. One of the variables considered to influence inhibitor development is the ABO blood group. Patients with blood group O have, on average, a 30%-40% lower endogenous von Willebrand factor (VWF) concentration. It has been postulated that VWF levels influence inhibitor development. The objective of this study was to investigate the inhibitor risk in patients with severe hemophilia A comparing those with blood group O with those with non-O blood groups.</p><p>METHODS: The study population consisted of children with severe hemophilia A, born between 2000 and 2020, who reached 50 FVIII exposure days in the PedNet registry. Inhibitors were considered to be clinically relevant when at least two consecutive measurements were tested positive.</p><p>RESULTS: Routine testing of blood groups varied between centres: Out of 1172 patients with severe hemophilia A, blood group status was known in 759 patients (65.8%). The relative risk of inhibitor development for blood group O in comparison to non-O was 1.04 (95% CI: 0.7-1.7).</p><p>CONCLUSION: In the PedNet cohort, blood group O did not increase the risk of inhibitors in previously untreated children with severe hemophilia A.</p><p>TRIAL REGISTRATION: PedNet Registry; clinicaltrials.gov identifier: NCT02979119.</p>}},
  author       = {{de Kovel, Marloes and van Haaster, Aimée-Claire and Carcao, Manuel and Ranta, Susanna and Glosli, Heidi and Rivard, Georges E and Kenet, Gili and Kurnik, Karin and Van Geet, Christel and Carvalho, Manuela and Andersson, Nadine G and Kartal-Kaess, Mutlu and Ljung, Rolf and van den Berg, H Marijke}},
  issn         = {{1351-8216}},
  language     = {{eng}},
  month        = {{03}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Haemophilia}},
  title        = {{Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A : Data from the PedNet Study Group}},
  url          = {{http://dx.doi.org/10.1111/hae.70035}},
  doi          = {{10.1111/hae.70035}},
  year         = {{2025}},
}